news
Update on the development of new novel cancer immunotherapy
The SCIB2 vaccine is to to be administered using new nanoparticle formulation in planned Phase 1/2 clinical trial.
List view / Grid view
t-cells
webinar
A high-throughput approach to developing T-cell immunotherapies
23 May 2019 | By Sartorius
Join us as we discuss the promises and pitfalls associated with developing individualised antigen-specific T-cell therapy products for clinical use.
news
Key step in the transformation of B-cells to antibody-secreting cells described
Scientists have detailed the role of a key controlling factor in the transformation of B-cells into antibody-secreting cells.
news
New technique developed to expand multimodal single cell analysis
A new technique, called ECCITE-seq, has been developed to allow researchers to perform high-throughput measurements of multiple modalities of information from single cells.
news
Heating up tumours could make CAR T therapy more effective
When a heating technique called photothermal ablation was combined with the infusion of CAR T cells, it suppressed melanoma tumour growth for up to 20 days in mice...
news
How the immune cell ‘Iron Man’ helps T-cells fight infection
The Iron Man of immune cells, the CD4 cell, has been found to help T-cells fight viral infections, with a lack of these cells often leading to illness...
news
Sartorius Stedim Biotech introduces BIOSTAT® RM TX with Flexsafe® RM TX for producing consistent quality cellular products
Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry announced the launch of the BIOSTAT® RM TX single-use bioreactor, a new wave mixed system developed specifically for closed, automated expansion of consistent quality cell products such as ex vivo cellular immunotherapies...
product
BIOSTAT® RM TX and Flexsafe® RM TX Bags
14 February 2019 | By Sartorius
The BIOSTAT® RM TX system consists of an automated control unit and a rocking platform, for gently agitating a single-use Flexsafe® RM bag...
product
Intellicyt® T Cell Activation Cell and Cytokine Profiling Kit
17 January 2019 | By IntelliCyt, a Sartorius Company
Multiplexed approach to measure T-cell activation, proliferation and quantify cytokine release in a single well
news
Engineered T-cells promote acceptance of organs after transplant
Controlling coronin 1 in T-cells could lead to the immune system not attacking transplanted organs, but still fighting other infections...
news
New therapeutic concept controls pathogenic T-cells relevant in MS
Researchers have identified an innovative and promising therapeutic option to treat multiple sclerosis...
news
Phospholipid reactive T-cells could play a role in cancer
Phospholipid-reactive T-cells that are able to recognise phospholipids could help in treatments against cancer, autoimmune diseases and dyslipidemia...
news
T-cells engineered to recognise tumours expressing the CD30 protein marker
Researchers have genetically engineered immune cells to recognise and fight Hodgkin and non-Hodgkin lymphoma cells...
news
War On Cancer 2018: targeted therapies in oncology
War On Cancer 2018 discussed how cancer treatments have evolved over the last few decades, and looked at the future of cancer therapies...
news
RIP1 kinase as a therapeutic target for pancreatic cancer
RIP1 has been shown to suppress the action of macrophages against the immune system and could be a potential therapeutic target for pancreatic cancer...
